MOSCOW, January 19. /TASS/. Results of the efficacy study of the Epivaccorona anti-coronavirus vaccine developed by the Vector State Research Center of Virology and Biotechnology will be made public in February, the center’s director, Rinat Maksyutov, said on Tuesday.

"Epivaccorona’s efficiency results will be made public in February. The vaccine’s efficacy is made up of its immunologic efficacy and protective efficacy," he was quoted as saying by the press service of the Russian sanitary watchdog.

The sanitary watchdog said earlier Epivaccorona had demonstrated 100% efficacy during the first and second stages of clinical tests.

To date, 3,612,800 coronavirus cases have been confirmed in Russia, with 3,002.026 patients having recovered from the disease. Russia’s latest data indicates 66,623 fatalities nationwide. Earlier, the Russian government set up an Internet hotline to keep the public updated on the coronavirus situation.